Pilot study demonstrates bacterial load differences in bladder cancer and healthy individuals, indicating possible diagnostic potential.
Recent studies utilizing 16S rRNA amplicon sequencing have challenged the notion of urine sterility, yet urine is a low-biomass specimen in which apparent community profiles can be strongly influenced by background signal from reagents and processing. To address this interpretability gap, we integrate culture-independent absolute 16S rRNA gene quantification with urinary 16S amplicon sequencing in a negative-control-anchored workflow. Bacterial load provides a biomass-aware quality control gate that defines interpretable low-biomass thresholds and objective exclusion criteria. As a pilot application, we compared midstream urine collected prior to instrumentation from healthy volunteers and newly diagnosed bladder cancer (BC) patients, quality filtering retained 29 controls and 5 BC cases. Samples > 106 copies/mL typically produced > 10 000 reads; near 105 copies/mL read counts dropped sharply yet remained distinguishable from background. Thirteen negative controls (V3–V4 PCR and stabilization buffer; median 90, mean 124 reads) supported excluding samples with < 1 000 reads. Median bacterial load was lower in BC than in controls (7.0×103 vs 1.07 × 106 copies/mL), although not significant in this underpowered cohort (p = 0.07). This cohort-size-independent framework enables load-based triage for sequencing, reduces background-driven over-interpretation in low-biomass urine datasets, and supports modelling bacterial load as a covariate or stratifier in future studies of the bladder cancer microbiome.
No takes yet. Share an insight, caveat, or question.
Accetto et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: